脊髄損傷(Spinal Cord Injury):治療薬開発パイプライン動向(2019年下半期版)

◆英語タイトル:Spinal Cord Injury - Pipeline Review, H2 2019
◆商品コード:MDATA4320993
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年11月
◆ページ数:209
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

The report provides comprehensive information on the therapeutics under development for Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

[Scope]
– The report provides a snapshot of the global therapeutic landscape of Spinal Cord Injury
– The report reviews pipeline therapeutics for Spinal Cord Injury by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Spinal Cord Injury therapeutics and enlists all their major and minor projects
– The report assesses Spinal Cord Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Spinal Cord Injury

[Companies mentioned]
AbbVie Inc
Algiax Pharmaceuticals GmbH
Aposcience AG
Athersys Inc
BioAxone BioSciences Inc
Cellatoz Therapeutics Inc
CellCure
CSL Ltd
CSPC Pharmaceutical Group Ltd
Daewoong Pharmaceutical Co Ltd
EUSOL Biotech Co Ltd
Fortuna Fix Inc
GABA Therapeutics Inc
GNT Pharma Co Ltd
Helixmith Co Ltd
Hemostemix Inc
Hibernaid Inc
Histocell SL
Hope Biosciences LLC
K-Stemcell Co Ltd
Kringle Pharma Inc
Lineage Cell Therapeutics Inc
Mapreg SAS
Mitsubishi Tanabe Pharma Corp
NervGen Pharma Corp
NeuExcell Therapeutics Inc
Neuronax SAS
Neuroplast BV
New World Laboratories Inc
Novago Therapeutics AG
Novartis AG
Novoron Bioscience Inc
NuNerve Pty Ltd
PharmatrophiX Inc
Pharmazz Inc
Pharmicell Co Ltd
PixarBio Corp
Q Therapeutics Inc
Radikal Therapeutics Inc
RDD Pharma Ltd
ReNetX Bio
RespireRx Pharmaceuticals Inc
SanBio Inc
Seneca Biopharma Inc
StemCyte Inc
Stemedica Cell Technologies Inc
Sumitomo Dainippon Pharma Co Ltd
TechnoPhage SA
Tumorend LLC
Xcelthera INC
ZyVersa Therapeutics Inc

【レポートの目次】

Table of Contents 2

Introduction 5

Spinal Cord Injury Overview 6

Spinal Cord Injury Therapeutics Development 7

Spinal Cord Injury Therapeutics Assessment 18

Spinal Cord Injury Companies Involved in Therapeutics Development 30

Spinal Cord Injury Drug Profiles 43

Spinal Cord Injury Dormant Projects 176

Spinal Cord Injury Discontinued Products 180

Spinal Cord Injury Product Development Milestones 181

Appendix 191

List of Tables

Number of Products under Development for Spinal Cord Injury, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Spinal Cord Injury – Pipeline by AbbVie Inc, H2 2019

Spinal Cord Injury – Pipeline by Algiax Pharmaceuticals GmbH, H2 2019

Spinal Cord Injury – Pipeline by Aposcience AG, H2 2019

Spinal Cord Injury – Pipeline by Athersys Inc, H2 2019

Spinal Cord Injury – Pipeline by BioAxone BioSciences Inc, H2 2019

Spinal Cord Injury – Pipeline by Cellatoz Therapeutics Inc, H2 2019

Spinal Cord Injury – Pipeline by CellCure, H2 2019

Spinal Cord Injury – Pipeline by CSL Ltd, H2 2019

Spinal Cord Injury – Pipeline by CSPC Pharmaceutical Group Ltd, H2 2019

Spinal Cord Injury – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2019

Spinal Cord Injury – Pipeline by EUSOL Biotech Co Ltd, H2 2019

Spinal Cord Injury – Pipeline by Fortuna Fix Inc, H2 2019

Spinal Cord Injury – Pipeline by GABA Therapeutics Inc, H2 2019

Spinal Cord Injury – Pipeline by GNT Pharma Co Ltd, H2 2019

Spinal Cord Injury – Pipeline by Helixmith Co Ltd, H2 2019

Spinal Cord Injury – Pipeline by Hemostemix Inc, H2 2019

Spinal Cord Injury – Pipeline by Hibernaid Inc, H2 2019

Spinal Cord Injury – Pipeline by Histocell SL, H2 2019

Spinal Cord Injury – Pipeline by Hope Biosciences LLC, H2 2019

Spinal Cord Injury – Pipeline by K-Stemcell Co Ltd, H2 2019

Spinal Cord Injury – Pipeline by Kringle Pharma Inc, H2 2019

Spinal Cord Injury – Pipeline by Lineage Cell Therapeutics Inc, H2 2019

Spinal Cord Injury – Pipeline by Mapreg SAS, H2 2019

Spinal Cord Injury – Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019

Spinal Cord Injury – Pipeline by NervGen Pharma Corp, H2 2019

Spinal Cord Injury – Pipeline by NeuExcell Therapeutics Inc, H2 2019

Spinal Cord Injury – Pipeline by Neuronax SAS, H2 2019

Spinal Cord Injury – Pipeline by Neuroplast BV, H2 2019

Spinal Cord Injury – Pipeline by New World Laboratories Inc, H2 2019

Spinal Cord Injury – Pipeline by Novago Therapeutics AG, H2 2019

Spinal Cord Injury – Pipeline by Novartis AG, H2 2019

Spinal Cord Injury – Pipeline by Novoron Bioscience Inc, H2 2019

Spinal Cord Injury – Pipeline by NuNerve Pty Ltd, H2 2019

Spinal Cord Injury – Pipeline by PharmatrophiX Inc, H2 2019

Spinal Cord Injury – Pipeline by Pharmazz Inc, H2 2019

Spinal Cord Injury – Pipeline by Pharmicell Co Ltd, H2 2019

Spinal Cord Injury – Pipeline by PixarBio Corp, H2 2019

Spinal Cord Injury – Pipeline by Q Therapeutics Inc, H2 2019

Spinal Cord Injury – Pipeline by Radikal Therapeutics Inc, H2 2019

Spinal Cord Injury – Pipeline by RDD Pharma Ltd, H2 2019

Spinal Cord Injury – Pipeline by ReNetX Bio, H2 2019

Spinal Cord Injury – Pipeline by RespireRx Pharmaceuticals Inc, H2 2019

Spinal Cord Injury – Pipeline by SanBio Inc, H2 2019

Spinal Cord Injury – Pipeline by Seneca Biopharma Inc, H2 2019

Spinal Cord Injury – Pipeline by StemCyte Inc, H2 2019



【レポートのキーワード】

脊髄損傷(Spinal Cord Injury)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[脊髄損傷(Spinal Cord Injury):治療薬開発パイプライン動向(2019年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆